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“ASSESSMENT OF CLINICAL CORRELATION BETWEEN 
BODY MASS INDEX AND SEVERITY OF BRONCHIAL 
ASTHMA” 
ABSTRACT: 
AIMS & OBJECTIVES: 
 To study the risk of Bronchial asthma severity with increasing body 
mass index. To study the significance between C- reactive protein and obesity. To 
assess the morbidity of bronchial asthma patients with increasing weight. 
 
METHODS: 
  We studied the association of body mass index (obesity) and severity 
of asthma in Rajiv Gandhi Government General Hospital, Chennai. We included 
known asthmatic adults, who were confirmed with reversibility spirometry test, 
between 20-40 years of age. A total of 100 patients were divided in to the 
following BMI classes according to Indian population standard. 61 normal (BMI 
class I – 18.5 to 22.9), 10 overweight (BMI class II – 23 to 24.9) and 29 obese 
patients (BMI class III  ≥ 25). Based on Global initiative for Asthma (GINA) 
severity classification, patients were divided in to 4 categories, 17 patients in Class 
I – mild intermittent asthma, 39 in Class II – mild persistent asthma, 24 in Class III 
– moderate persistent asthma and 20 in Class IV – severe persistent asthma. 
Patients were assessed by history, pulmonary function tests (FVC, FEV1, 
FEV1/FVC ratio, PEFR) and SpO2. C-reactive protein was done to assess the 
correlation with body mass index. 
RESULTS: 
  Compared with normal weight asthmatic patients obese individuals 
were most likely to have missed working days, life threatening events, low SpO2, 
low FEV1/FVC ratio and high C-reactive protein. They were more likely to have 
severe persistent asthma than non-obese individuals. 
CONCLUSION: 
  In our study, obesity has significant association with severity of 
asthma. It increases the burden to life very much. So in treatment plan of obese 
asthmatics, weight reduction strategy must be included with other measures. 
KEY WORDS: 
  Body mass index, Pulmonary function tests, C-reactive protein. 

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INTRODUCTION 
 
 Bronchial asthma is defined by GINA1 as a “chronic inflammatory 
disorder of airways, in which cell and cellular elements play a major role. This 
chronic inflammation leads to airway hyper responsiveness that cause recurrent 
wheezing, breathlessness, chest tightening and coughing particularly at night or 
in the early morning. These episodes will be usually associated with wide 
spread, but may be variable, airflow obstruction within the lung and is often 
reversible either spontaneously or with the treatment”. 
 
 Many trigger factors and co morbid conditions that will increase 
asthma symptoms and precipitate asthma exacerbations are obesity, gastro 
esophageal reflex disease, corticosteroid insensitivity, aspirin sensitivity, 
sinusitis, environmental exposure and genetics2,3,4. 
 
 Asthma and obesity are major public health problem in India. Both 
conditions are more prevalent nowadays. Many literatures correlate these 
conditions.  Many recent studies show that obesity is a main contributing factor 
for asthma and also explains a significant relationship between BMI and 
development of asthma. Some literatures have even explained that weight gain 


provokes the asthma symptoms and similarly weight loss improves the 
symptoms. 
  
 Many theories explain the association between obesity and asthma. 
Already we know that obesity causes reduction in pulmonary compliance, 
diameter of terminal airway mainly located in the periphery, lung volumes, lung 
blood volume and also ventilation-perfusion relationship. 
 
         Recent theories explained that the increase in adipocytes in obese 
individuals can cause systemic pro-inflammatory state. Fat cells raise the serum 
level of many cytokines, chemokines and soluble fractions of their receptors.  
 
 Adipose tissue secretes and also synthesizes many factors which 
are called adipokines. They include  
• Interleukin-10  
• Interleukin-6 
•  Tumour necrosis factor-α 
•  TGF-β1 
•  Eotoxin  
• C-reactive protein 
•  Leptin and adiponectin. 


 
 Further more bronchial asthma and obesity both have related 
specific human genome. The normal pattern of growth of the body and the tone 
of airways are altered by diet and genes. 
 
   The response of treatment to asthmatic patient is affected by 
obesity. Peters-Golden et al, analyses the treatment response to asthmatic 
patients with BMI by placebo, inhalational corticosteroids and antagonist to 
leukotriene receptor. In this study,  
• The placebo received patients had greater under control of 
asthma in normal weight patients than overweight and obese 
patients.  
 
• In patients receiving inhaled corticosteroids 
(beclomethasone) there was no changes in drug efficacy with 
weight.  
 
• In patients receiving leukotriene receptor antagonists 
(monteleukast), clinical benefit was greater in high BMI (obese) 
patients than thin individual, which revealed that in obese patients, 
leukotriene are important mediators of symptoms. 


 
 
 The first and foremost object of this study is that weight control 
program should be included in obese asthmatic management and also the 
normal response of asthmatic treatment may be disturbed by obesity 
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AIMS AND OBJECTIVES 
 
 To study the risk of Bronchial asthma severity with increasing body mass 
index. 
 
 To study the significance between C- reactive protein and obesity. 
 
 To assess the morbidity of bronchial asthma patients with increasing 
weight 
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REVIEW OF LITERATURE 
  
OBESITY 
 
  Obesity is defined as abnormal accumulation of fat in the form of 
adipose tissue in various parts of the body which may cause many health 
problems. However, the site of distribution of fat is very important than the 
amount of fat. So excess abdominal fat is a major risk factor for many diseases. 
 
PREVALENCE: 
 
  According to the NHANES data, in the American adult population, 
obesity may raise from 14.5% to 30.5%. In this data, >20years of age are more 
obese. Extreme obesity is increased to 4.7% of people. Obesity is increased in 
women and poor population. Recently prevalence of obesity is high in 
paediatric population. 
 
  
5In 1960s, the prevalence of obesity was 11% in men and 16% in 
women. By NHANES II and NHANES III study, between 1976 and 1980, 1988 
and 1994, the prevalence of obesity was 25% in men and 26% in wome. 
5During 2003-2004, the prevalence of obesity increased to 32% in men and 34% 

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in women. In short period of time from 1999 to 2004, the rate of prevalence of 
obesity significantly increased.   
 
EPIDEMIOLOGICAL OBSERVATIONS: 
 
1. CROSS SECTIONAL STUDIES: 
 Several studies revealed that increased incidence of bronchial 
asthma is seen in obese patients. All the studies have significant data and 
large number of patients. Data taken for BMI estimation like height and 
weight was self reported.  In Some studies, asthma was diagnosed and 
classified according to clinical history and previous diagnosis. It explained 
that, even the asthma and obesity related with other problem like sleep 
apnoea and GERD, the association between high BMI and asthma increased 
significantly6,7,8. 
 
2. PROSPECTIVE STUDIES: 
 
 Many studies showed that the obesity is a major risk factor 
for the asthma, and increases risk from 1.1 times to 3 times9,10,11.  In 
another study, more individuals were included and longer time followed 
up for longer time. This showed   increased incidence of development of 
asthma around 10% in men and 7% in women per unit increase in Body 
	
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Mass Index. In conclusion, the study showed positive correlation between 
the BMI and increasing asthma. So we can conclude that the increase in 
weight paves place for developing asthma 
 
3. STUDIES IN PEDIATRIC POPULATIONS 
 
  Many studies were conducted in pediatric populations to 
assess the strength of results and direction of relation between asthma and 
obesity which shows that they are heterogeneous. One study12, conducted 
in 9828 children between 6 to 14 years of age. It revealed the significance 
of obesity in increasing the risk of asthma, particularly in girls. Another 
study13, conducted in the same time in 3795 children showed that the risk 
of asthma increased, when person became overweight and obese, which is 
particularly more in boys than in girls.  
 
 A study conducted in 4720 persons born in the year of 1996 
by Finnish et al14, revealed that increasing weight in early life, increases 
the risk of asthma in adult life. In most recent studies15 conducted in 4393 
children, who had no symptom of asthma in first two years of life, were 
followed up to 14 years, the observation showed that the group of 
individual with high BMI had 2.5 fold increased  risk for developing 
bronchial asthma when compared with low BMI individuals. In children 



participating NHANES III, the association was found mainly between 
BMI and bronchial asthma, but not with atopy. 
 
4. STUDIES INCLUDING WEIGHT CHANGES: 
 The Nurse Health study9 showed that the involved persons 
who increased weight greater than 25 kg from the 18 years of age, the 
probability for development of asthma rose 4.7 times than those whose 
weight remained stable. Weight loss by surgery improved the patient 
symptomatically and good treatment response and reduced duration of 
hospital admission16. Weight loss achieved by diet will improve the lung 
function in obese asthmatics. 15% reduction in body weight may lead to 
better results in FEV1, FVC, lower symptom scores and decrease 
frequency of medication use. 
 
HYPOTHESIS FOR ASSOCIATIONOF ASTHMA AND OBESITY 
PHYSIOLOGICAL CHANGES IN OBESITY: 
 
  Weight gain (obesity) can reduce the pulmonary compliance, lung 
volume, volume of blood in lungs, diameter of airways which are located in 
periphery and ventilation-perfusion relation. In obese patients, more deposition 
of fat can compress and infiltrate the thorax and thereby can causes reduction of 
pulmonary compliance. All the above factors can increase the symptom of 

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dyspnoea17. The obesity can produce limitation of the airflow with reduction in 
FEV1 and FVC. This leads to symmetrical reduction in FEV1 and FVC, so the 
ratio between these remains the same. Sometimes this ratio may be like 
restrictive models18 in overweight individuals. This change in lung physiology 
in obese individuals can cause superficial respiration with reduction of lung 
volume like expiratory reserve volume. This lung volume reduction is 
associated with peripheral airway diameter reduction, which produces change in 
the smooth muscles of airways that increase the obstruction and bronchial hyper 
reactivity19. 
OBESITY AND INFLAMMATORY MEDIATORS: 
        Recent theory explained that the increased adipocytes in obese 
individuals can cause systemic pro-inflammatory state. Fat cells raise the serum 
level of many cytokines, chemokines20 and soluble fractions of their receptors.  
Adipose tissue secretes and also synthesizes many factors which are 
called adipokines. They include  
 Interleukin-6 & 10  
  Tumour necrosis factor-α 
  TGF-β1 
  Eotoxin  
 CRP 


  Leptin and adiponectin 
 
 
TUMOR NEROSING FACTOR -α: 
 TNF-α is produced in adipocytes. It is elevated in asthma patients. It 
produces TH2 cytokines of IL-4, IL-6 in the epithelium of bronchial airways. 
High TNF-α level leads to release of higher amount of cytokines. 
IL-6, IL-10: 
 Serum IL-6 level increased in obese Individuals. It is associated with risk 
of severe bronchial asthma21. In obese mice, treated with anti IL-6, it was found 
that there was reduction in bronchial hyper reactivity. This result was not found 
in normal mice, which had the same treatment22. 


 
LEPTINS: 
   
 A lot of articles explain the role of leptin in relation between 
bronchial asthma and obesity. Leptin is a hormone. It is produced in adipocytes, 
as well as in hypothalamus, placenta and ovaries, which is elevated in obese 
individuals. Leptin acts as lipostat. When there is increase in fat storage in 
adipocytes, leptin is released in to the bloodstream. Increased leptin in blood 
sends the negative feedback signals to hypothalamus and releases more 
anorexigenic peptides and less orexigenic peptides. 
 
 “Leptin” plays a role in inflammation in obese individuals. It 
produces proliferation and activation of T-cells. It recruits the monocytes and 
macrophages and promotes angiogenesis. 
 
  “Leptin” has a role in the development of lung and critical 
mediator for differentiation between the lipofibroblast, fibroblast and also in the 
synthesis of lung surfactants24. In animal models, administration of leptin 
preparation exogenously will increases inflammation in lung25 and also alters 
serum IgE levels. Leptins increase the bronchial hyper reactivity by allergens26. 

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In humans, leptin level is most important factor to predict the development of 
asthma, particularly in children27.  
 
 
 
 


 
Central pathway – regulation of leptin to maintain the body weight and 
appetite 
 
  One study conducted in 5870 individuals of women with the 
asthma had an increased level of leptin than those without have asthma28.  
 
 
 
 
 

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ADIPONECTIN: 
 
  Serum adiponectin levels are reduced in obese individuals. This 
hormone has important role in anti-inflammatory action in the airway 
epithelium29. Decreased level of adiponectin in asthmatic individuals can 
provoke the symptoms, which implies the role between obesity-asthma 
relationships.  
 
EOTOXIN: 
 
  Systemic eotoxin increased in obese persons, which is synthesized 
in adipocytes, plays potential role in severity of asthma in obese individuals30. 
 
GENETIC FACTORS: 
 
  In human genome, specific regions are linked to obesity and 
bronchial asthma.  
• chromosome 5q 
• chromosome 6 
• chromosome 11q13 and 12q31 
 

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• Chromosome 5q 
Chromosome 5q codes for genes ADRB2 and NR3C1. The 
ADRB2 gene contains the regions for β2- adrenergic receptors which is 
important to maintain the tone of airway and baseline metabolism. 
NR3C1 gene – codes for glucocorticoid receptor, important for 
inflammatory response in obesity and asthma. 
• Chromosome 6: 
Chromosome 6 codes the genes for TNF-α, that is important for 
anti-inflammatory response and immune response in bronchial asthma 
and also in obesity. 
 
• Chromosome 11q13: 
Chromosome 11q13 has loci for proteins UCP2-UPC3. It also has 
loci for low affinity IgE receptor. The UCP2-UCP3 protein is important 
for baseline metabolism. The “low affinity IgE receptor” produces 
inflammatory response to TH2 cells. This level increases in asthma 
patients. 
 
• Chromosome 12q: 
Chromosome 12q contains loci for inflammatory cytokines for 
asthma, LTA4H, IFN-γ, nitric oxide synthase-1. It also contains 


inflammatory mediators for obesity like CD36L1, STAT6, type I 
insulinoid growth factor 
 
o β3 adrenergic receptors located in the adipose tissue which 
maintain the lipolysis and thermogenesis. Genetic mutation of the 
gene for β3adrenergic receptor has the capacity to increase 
weight32. 
 
HORMONAL FACTORS: 
 
  One longitudinal study was carried out and it showed that the effect 
of weight gain over bronchial asthma is greater in female than male. The 
enzyme aromatase converts androgens to estrogens. It is present in adipose 
tissue. The obese women produce increased level of oestrogen, which is related 
with the early menarche in female and delayed puberty in male35, 36. 
 
   Tueson 37cohort study revealed that the number of patients with 
asthma was very high in overweight females who attain menarche earlier than 
those attaining menarche at later stage. This suggests that obesity disrupts the 
hormone production in girls at puberty. This increased production of female 
	

hormones has altered the lung development and airway tone in the girls of 
pubertal age. 
 
 DIET FACTORS: 
 
  Many diet related to the high number of asthma patients in adults 
and children. Vitamin C, Vitamin E, riboflavin, carotene, pyridoxine and 
minerals produce improvement in immune function and reducing the severity of 
asthma. 
 
  Romieu et al38 explained that the women consuming vegetables, 
fruits and green-leaves have lower incidence of asthma.  Trans-fatty acid 
containing food consumption in children is linked to reduced prevalence of 
asthma39. 
 
IMPLICATION FOR TREATMENT: 
 
  The response of treatment to asthmatic patient is affected by 
obesity. Peters-Golden et al43, analyses the treatment response to asthmatic 
patients with obesity by placebo, inhalational corticosteroids and antagonist to 
leukotriene receptor. In this study,  


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• The placebo received patients had greater control of asthma in 
normal weight patients than overweight and obese patients.  
 
• In patients receiving inhaled corticosteroids (beclomethasone) 
there was no changes in drug efficacy with weight.  
 
• In patients receiving leukotriene receptor antagonists 
(monteleukast), clinical benefit was greater in high BMI (obese) 
patients than thin individual, which revealed that in obese patients, 
leukotrienes are important mediators of symptoms. 
 
 Another study conducted to compare the efficacy of placebo, 
theophylline and monteleukast to the overweight asthmatic patient. The patients 
treated with theophylline have worsening symptoms of asthma in obese than 
lean asthmatic patients. But symptoms improved with monteleukast in obese 
asthmatics. 
 
 
 
 

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COMPLICATIONS OF OBESITY:   
 
  Obesity and overweight is a second leading cause of death in US, 
more complication associated with greater intra abdominal fat accumulation 
than other parts. Life expectancy has shortened by 2-5 years in moderately 
obese. Patient with BMI > 45, particularly male, will loss 13 years of life. The 
following are the complications.  
 Asthma 
 Malignancy 
 Coronary artery disease 
 Dementia 
 Depression 
 Diabetes 
 Impaired Fertility and reproduction 
 Gastro-esophageal reflux disease 
 Kidney disease 
 Liver disease 
 Increased mortality 
 Osteoarthritis 
 Pancreatitis 
 Sleep disorders 


 
MEASUREMENTS: 
BODY MASS INDEX: 
                One of the commonly used indices. This is defined as body weight 
in kilogram (kg) divided by height (meters) squared. 
 
BMI= WEIGHT (kg) / HEIGHT (meters)2 
 
WEIGHT STATUS CLASSIFICATION ACCORDING TO BMI 
 
 
Classification 
 
 
BMI (kg/m2) 
 
Risk of co-morbidities 
 
Underweight 
 
 
<18.5 
 
Low 
 
Normal weight 
 
 
18.5 – 24.9 
 
Average 
 
Overweight: 
 
Pre obese 
 
 
≥25 
 
25 – 29.9 
 
 
 
Increased 
 
Obese class I 
 
 
30.0 – 34.9 
 
Moderate 
 
Obese class II 
 
 
35.0 – 39.9 
 
Severe 
 
Obese class III 
 
 
≥40.0 
 
Very severe 
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BMI FOR ASIAN POPULATIONS: 
 
  The classification of obesity in Asian population showed increased 
risk of co morbidities of obesity occur in lower BMI in Asian population 
 
 
Classification 
 
 
BMI (Kg/m2) 
 
Risk of Co-morbidities 
 
Underweight  
 
 
<18.5 
 
Low 
 
Normal range 
 
 
18.5 – 22.9 
 
Average 
 
Overweight 
 
At risk 
 
Obese class I 
 
Obese class II 
 
 
>23.0 
 
23.0 – 24.9 
 
25.0 -  29.9 
 
>30 
 
 
 
Increased 
 
Moderate 
 
Severe 
 
 
 
 
 
 
 
 

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WAIST CIRCUMFERENCE AND WAIST-HIP RATIO: 
 
  Excess of abdominal fat is a predictor of risk factor and morbidity 
related to obesity like type II diabetes, systemic hypertension, dyslipidemia and 
ischemic heart disease. So waist circumference is one of the valuable additional 
methods to measure abdominal fat and identify the individual at increased risk. 
In Caucasians, the waist circumference of 94cm and above for men, 80cm and 
above for women has increased risk. In Asians 90cm and above for men, 80cm 
and above for women has increased risk. 
   
CUT-OFF POINTS OF WAIST CIRCUMFERENCE FOR INCREASED 
RISK: 
  
MALE 
 
 
FEMALE 
 
WHO 
 
 
94cm (37 inches) 
 
80cm (32 inches) 
 
Asians 
 
 
90cm (35 inches) 
 
80cm (32 inches) 
  
Over the last decades, the high waist-hip ratio (>1.0 for men, >0.85 for 
women) accepted as one of the predictor for identifying patients with abdominal 
adipose tissue accumulation. 


 
Measuring waist circumference 
 
 
 
 

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MANAGEMENT OF OBESITY 
 
WEIGHT LOSS AND MAINTENANCE: 
 
1. DIET APPROACH: 
 
 Majority of obese patients required to reduce the calorie intake and 
modify the diet pattern according to calories. The dietary therapy for overweight 
patients is low calorie diet, which contain total calorie 800-1500 kcal per day. 
Low calorie diets contain all the nutrients and also decrease the other risk 
factors like high cholesterol and hypertension. In dietary therapy patient should 
be educated for 
 Nutrient value of food 
 Composition of food 
 Reading nutrition label to know the calorie contents 
 New habits to purchase low calorie diet 
 During the food preparations, avoid adding high calorie ingredients 
like fat and oils. 
 Avoid more consumption of high calorie food 
 Maintain adequate water intake 
 Limiting alcohol consumption 


2. PHYSICAL ACTIVITY: 
 
 Increased physical activity alone can produce up to 2-3% 
weight loss. If associated with LCD the promoting weight loss is more. 
The physical activity alone can reduce the CVD risk factor. 
 
 
3. BEHAVIOUR THERAPY: 
 
 Behavior therapy is provided to overcome the barrier for 
compliance with dietary therapy and physical activity. So behavior 
therapy is an important in weight reduction treatment. Most of the 
program includes the behavior therapy as packages with nutrition and 
physical activity.  
 
4. COMBINED THERAPY: 
 
 To achieve the maximum benefit of weight reduction 
required the three components like dietary approach with LCD (low 
calorie diet), behavior therapy and exercise. This regimen should be 
followed for 6 months before starting pharmacotherapy. 
 
5. PHARMACOTHERAPY:
 
 No drug is approved by FDA for long term use more than 3 
months. Weight loss dru
 
 for  weight loss treatment 
 If  BMI > 30 without obesity related co
 If  BMI > 27 with obesity related co
 
 
  
 
 
 
	

 
gs are indicated,  
 with dietary and physical activity
-morbidities
-morbidities 
 
 
 


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 Weight reduction drugs should be used with lifestyle 
modifications.  During the period of treatment, Continuous monitoring of 
drug efficacy and complication is necessary. Any drug potent to reduce 
the weight without the serious side effects, that drug can be continued. 
Otherwise it can be discontinued, and proceeded with surgery 
 
6. SURGICAL MANAGEMENT: 
 
           Surgery is indicated in patient who are very obese, and when other 
therapies have failed and who are affected by the complication of obesity. 
Surgical intervention methods are gastroplasty, gastric partitioning, 
gastric bypass and vertical gastric banding. 
 
 
 
 
 
 
 
 
 
 
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BRONCHIAL ASTHMA 
 
DEFINITION: 
 
  ATS/ERS44 definition: Asthma is defined as “a clinical syndrome, 
characterized by increased trachea-bronchial tree responsiveness for a variety of 
stimuli. Major symptoms are paroxysms of dyspnoea, cough and wheezing, 
which may vary from mild to severe (status asthmaticus). The primary 
manifestation of this hyper-responsiveness is airways obstruction which is 
variable. This occurs like spontaneous fluctuations of severity of obstruction 
with substantial improvement in severity of obstruction followed by 
corticosteroids or bronchodilators, or increased severity of obstruction by drugs 
and other stimuli” 
 
  NIH definition45: “Asthma is characterized by repeated episodes of 
wheeze and dyspnoea, which is associated with partially reversible airway 
obstruction. Pathologically, it is defined inflammation of airways with 
infiltration of T cells, eosinophils and mast cells. Physiologically, increased 
airway responsiveness and immunologically, increased production of IgE 
antibodies to the environmental allergies” 
 
 

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EPIDEMIOLOGY OF ASTHMA 
 
PREVALENCE: 
 
  Asthma is a major problem worldwide, affecting 300 million 
people. Based on standardized methods, the prevalence of asthma and wheezing 
in children and adults ranges from 1% to 18% of populations in worldwide46. In 
2002, CDC conducted one survey which showed 72 individuals per 1000 (or) 
20 million individuals have asthma and also observed that the rates are 
decreased with ages. Between 0 – 17 years 83 per 1000 children were affected 
compared to 68 per 1000 above 18 years.  
 
   
  Childhood asthma from population based prevalence estimated in 
India, the prevalence is increased in secular trend47. The incidence of new onset 
of asthma episodes in childhood is increased progressively. The median 
prevalence of childhood asthma in India is 3.3%, suggesting that childhood 
asthma prevalence is rising in India. 
  
 

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  Jain et al48, study showed that the prevalence of asthma to be 
10.3% in South India. This is higher among the boys than girls. There was 
inverse association between increasing age and family history of asthma. 
 
SOCIO-ECONOMIC BURDEN IN BRONCHIAL ASTHMA: 
 
  From asthma studies conducted in India, Latin America, Asia-
Pacific, US and UK49, the major socio-economic burden is absence from school 
and work. In New Zealand, 80% of resources are utilized for asthma patients 
and in India the cost of medication is estimated to be US$30 per month50. The 
monetary cost is estimated in UK and US are substantial51. By analysis of 
economic burden it was reported that attention need to put in both direct 
medical cost and indirect medical as well as non-medical costs52. Bronchial 
asthma is a major cause for absence from work which is a major burden in 
many countries, and it can be reduced by health care providers53, individual 
efforts and asthma care organizations.  
 
MORTALITY:  
 
  The WHO estimated that, due to asthma, about 15 million DALYs 
are lost in a year. It represents about 1% of global disease burden53.  Death rates 

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annually due to bronchial asthma is estimated to be 2, 50,000 in worldwide 
which does not correlate with prevalence54. 
 
ETIOLOGICAL FACTORS FOR DEVELOPMENT OF BRONCHIAL 
ASTHMA 
 
HOST FACTORS: 
 Sex  
 Obesity 
 Genetic  
 
ENVIRONMENTAL INFLUENCES: 
 
 Allergens – mites, fungi, molds, yeasts, pollens, cockroach allergen. 
 Infections 
 Occupational sensitizers 
 Air pollution 
 Diet  
 Smoking – active and passive 
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HOST FACTORS: 
 
SEX: 
 
  The prevalence of asthma in younger age group before 14 years is 
twice common in boys than the girls. In more than 14 years of age group, 
female affected than male. 
 
 
OBESITY: 
 
         Recent theory58 explained that the increase in adipocytes in fats in 
obese individuals can cause systemic pro-inflammatory state. Fat cells raise the 
serum level of many cytokines, chemokines and soluble fractions of their 
receptors.  
Adipose tissue secretes and also synthesizes many factors which 
are called adipokines. They include Interleukin-10, Interleukin-6, Tumour 
necrosis factor-α, TGF-β1, Eotoxin, C - reactive protein, Leptin and adiponectin 
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GENETIC FACTORS: 
 
  Multiple genes55 are involved in development of bronchial 
asthma. The genes responsible for asthma has been coded on following,  
• Production of allergen specific  IgE56 antibody 
• Generation of inflammatory mediators 
• Expression of airway hyper-responsiveness 
• Determination of immune response 
  
 Chromosomal regions associated with susceptibility have been 
identified by several studies. For example, the gene responsible for elevated 
levels of IgE is located near major locus 5q.  
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ENVIRONMENTAL FACTORS: 
 
ALLERGENS: 
 
 Many studies62 explained that the indoor and outdoor allergens 
exposure and sensitization like house dust mite allergen, dog dander, cat dander, 
fungi  are risk factors for development of asthma in children <3 years. 
 
 
INFECTIONS: 
 
 Viral infections during infancy like parainfluenza virus, RSV may 
produce asthmatic symptoms in childhood. 40% RSV infected children have 
shown to continue to wheeze and develop asthma in later life58, 59. In some 
studies, infection with RSV and measles has shown protection against asthma 
development60. “The hygiene hypothesis” of asthma explains that early affected 
by infection in children leads to production of immune response in non allergic 
pathway thereby reducing the risk of development of asthma  
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OCCUPATIONAL SENSITIZERS: 
 
 Occupational sensitizer is defined as an agent, which is present in 
working environment leading to asthma. Occupational asthma61 is associated 
with over 300 substances.   
 
 Smoking -tobacco: 
 
 Smoking is associated with reduction of lung function and 
increased asthma severity. It reduces the response to treatment with inhaled or 
systemic steroids. During pregnancy, maternal smoking has got the influence in 
lung development of the fetus.  Infants of smoking mothers have 4 times more 
risk of developing wheeze in first year of life. 
 
 
Air pollution: 
 
 Indoor and outdoor air pollution increases the risk of asthma 
exacerbations. It may be related to increased level of sensitized allergens.  
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Diet: 
 
 Children fed with cow’s milk or formula feed have shown 
wheezing in early life when compared to children fed with breast milk. 
Increased use of processed foods, decreased antioxidants, decreased n-3 poly 
unsaturated fatty acids, and increased n-6 poly unsaturated fatty acids have been 
associated with recent increases in asthma and atopic diseases. 
 
FACTORS CAUSING EXACERBATIONS OF ASTHMA 
 
INFECTIONS: 
VIRAL INFECTIONS: 
 80-85% of asthma exacerbations are associated with viral 
infections of the respiratory tract and two-third of infections is being due to 
picarnovirus. Next most common virus is corona virus which causes less severe 
exacerbation of bronchial asthma. Influenza virus, adenovirus, RSV, 
parainfluenza causes more severe exacerbations of bronchial asthma. Human 
metapneumo virus, a paramyxovirus, closely related to RSV can cause acute 
exacerbations of asthma in infants and young children. 
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RESPIRATORY SYNCYTIAL VIRUS: 
 
                It mainly affects all the children below 2 years of age. RSV is the 
common cause for bronchiolitis in infants and children. The pathogenesis of 
bronchiolitis is not clear. Two types of bronchiolitis is caused by RSV, 
1. Eosinophil – positive bronchiolitis and 2.Eosinophil – negative bronchiolitis. 
 
               Infants most commonly affected by Eosinophil positive type may 
develop childhood asthma which induces strong TH2 response. 
 
RHINO VIRUS: 
 
 Rhino virus is the most common cause for LRI and acute 
exacerbation of asthma in less than 2 years of age. Previously it was thought 
that rhino virus mainly affects upper respiratory tract. But now it is proved that 
optimal replication of rhino virus occurs in 33°C – 35°C. Thermal mapping of 
airways is an important mechanism to replicate the rhinovirus in lower 
respiratory tract. 
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BACTERIAL INFECTIONS: 
 
 Sino nasal inflammation significantly worsens the lower airway 
disease. Organisms cultured from maxillary sinus aspirate are Moraxella 
catarrhalis, H.influenza and Streptococcus pneumonia. Effective treatment for 
sinusitis can improve the clinical symptoms of ashma32. Chronic sinusitis is also 
playing important role in difficult to control asthma. In asthmatic patients 
respiratory airway epithelium shows goblet cell hyperplasia which increases 
production of mucus secretion. This increased mucus secretion can act as nidus 
for localized infection which will produce invasive infection to other sites. 
 
ATYPICAL BACTERIAL INFECTION: 
 
 Mycoplasma pnemoniae and Chlamydia pneumonia significantly 
affect children, especially causing recurrent episodes of wheezing. It plays a 
potential role in exacerbation of childhood asthma. The incidence is increased 
with age. Telithromycin, a new ketolide antibiotic, can control the acute 
exacerbation of asthma. The ketolide and macrolide antibiotics have immuno-
modulatory effects in vivo and in vitro, on migration of neutrophils and 
production of pro-inflammatory mediators32. 
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ALLERGENS: 
 
Aeroallergens: 
 
 Epidemics of asthma exacerbation occur in late spring and 
summer. In this season, the level of Alternatio and Claudosporium species is 
increased. Sensitization to these moulds is associated with asthma exacerbations 
and hospitalization. Sensitization to mites, cockroaches and cats is found to 
have a significant association with worsening of asthma symptoms. 
 
Food additives and allergens: 
 
 Sulphites are used as preservatives in drugs and foods like, 
dehydrated vegetables, fruit mixtures and dried fruits. Sulphites agents are 
sulphur dioxide, sodium sulphite, sodium and potassium bisulphite, and meta 
bisulphate. Exposures to sulphites can cause significant bronchospasm in airway 
smooth muscles. The major food products producing asthma in children include 
milk, wheat, soy, eggs, fish, peanut, shellfish and tree nuts. 
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EXPOSURES 
OCCUPATIONAL SENSITIZERS: 
 
 Occupational asthma is defined as bronchial inflammation caused 
by direct inhalation of dust, fumes, gases and vapours in work place. Allergic 
occupational asthma caused by exposure to high molecular weight allergens and 
some low molecular weight allergens. HMW agents are protein derivatives from 
food, plants and animals, which stimulate the TH2 immune response with 
production of IgE. LMW agents, like antibiotics and metals, also stimulate the 
TH2 response. 
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ENVIRONMENTAL EXPOSURE: 
 
 Environmental factors associated with worsening of asthma 
symptoms are exercise, tobacco smoke, cold air, environmental pollutants. 
Exercise induced asthma causes the transient narrowing of airways followed by 
exercise. “The thermal hypothesis” is the main mechanism for 
bronchoconstriction after exercise. Exercise induced asthma individuals show 
increased production of cysteinyl leukotrienes in sensory nerve ends. 
 
 Outdoor polluted air can cause asthma exacerbations. Polluted air 
contains mixture of nitrogen dioxide, lead, ozone, sulphur dioxide and carbon 
monoxide. Motor vehicle exhaust emission contains carbon, carbon monoxide 
and nitrogen dioxide. Short term exposure to this emission produces 
neutrophilic inflammation of airways27. 
 
 Tobacco smoke exposure is a significant risk factor for asthma 
exacerbations. According to recent studies, smoking in the home is significantly 
related to asthma exacerbation in pre-school children37. 
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HORMONAL FACTORS: 
 
                     Some female shows the premenstrual worsening of asthma. The 
mechanisms are not completely understood. Some theories explain this due to 
reduction of progesterone. Hypothyroidism and hyperthyroidism both will 
worsen the asthma.  
 
DRUGS: 
 
 Aspirin and other NSAIDs and beta blockers are associated with 
asthma exacerbations 
 
GERD: 
 
 Clinical and experimental data have been demonstrated that GERD 
can cause bronchial asthma. Mechanism for GERD induced asthma is mainly 
due to vagally mediated reflux theory and micro aspirations. The prevalence of 
GERD among asthma patients is wide, ranging from 30% to 90% in several 
studies6-9.  
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CLASSIFICATION OF ASTHMA SEVERITY 
 
 According to GINA guidelines, the severity of bronchial asthma is 
classified based on symptoms, airflow limitations and pulmonary function tests. 
 
1. Intermittent asthma 
2. Mild persistent asthma 
3. Moderate persistent asthma 
4. Severe persistent asthma 
 
 
INTERMITTENT ASTHMA: 
 
 Symptoms <1 time in a week 
 Asymptomatic 
 Symptoms in night <2 times in a month 
 FEV1 > 80% 
 PEFR variability <20% 
 
 
 
 


MILD PERSISTENT ASTHMA: 
 
 Symptoms >1time in a week, <1 time in a day 
 Attacks may affect activity 
 Night time symptoms >2times in a month 
 FEV1 > 80% 
 PEFR variability 20-30% 
 
MODERATE PERSISTENT ASTHMA: 
 
 Symptoms occur daily 
 Attacks affects activity 
 Night symptoms > 1time a week 
 FEV1 60-80% 
 PEFR variability  > 30% 
 
SEVERE PERSISTENT ASTHMA: 
 
 Continuous symptoms of wheezing 
 Restriction of physical activity 
 Frequent symptoms in night  
 FEV1 < 60% 
 PEFR variability > 30% 
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CRITERIA: 
 
 The presence of one of the above feature of severity is enough to 
place a patient in that category. 
 
 
CLINICAL FEATURES 
 
Symptoms: 
 
 Wheezing 
 Dyspnoea / tachypnoea 
 Coughing 
 Patient feels difficulty in filling of air in lungs 
 Symptoms worsening at night and wake  up in early morning 
 Increased mucus production 
 
 
Signs: 
 
 Inspiratory and expiratory rhonchi all over the chest 
 Accessory muscles acting 
 Tachypnoeic 
 Silent chest in severe asthma 
	
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DIAGNOSIS 
 
 Usually diagnosed by symptoms of airway obstruction and 
objective measurement of pulmonary function test. 
 
Pulmonary function tests: 
 
 Spirometry shows reduced FEV1, FEV1/FVC ratio and PEF. 
  
 Reversibility test can be documented by > 12% and 200ml 
increases in FEV1 after 15 minutes of inhalation of short 
acting beta 2 agonists or 2 to 4 weeks trial of oral 
corticosteroids. 
 
 PEFR variability twice daily in morning and evening 
measurements confirm the diurnal variations of air flow 
obstruction. 
 
 Flow volume loop shows reduced maximum expiratory flow 
and reduced peak flow rate. 
 
 Other lung functions are rarely needed. 
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Airway responsiveness: 
 
 Airway hyper responsiveness is normally measured by histamine 
challenge or methacholine test. This is rarely useful nowadays in clinical 
practice. In suspected exercise induced asthma, exercise test is done for 
demonstration of post exercise bronchoconstriction. 
 
 
Hematological tests: 
 
 Blood tests are not helpful. Total serum IgE and specific IgE for 
inhaled allergens (RAST – radio allegro sorbent test) are measured for some 
patients. 
 
Chest x-ray: 
 Chest X-ray will be normal. Some patients may show hyper-
inflated lung. 
 
Skin tests: 
 
 Skin prick tests for common inhalant allergens will be positive in 
allergic asthma. But this is not useful for diagnosis. 


 
Exhaled nitric oxide: 
  
 It is a non-invasive test to measure airway inflammation. Increased 
level of exhaled nitric oxide in asthma is reduced by inhalational corticosteroid 
therapy. So it will be useful to demonstrate sufficient anti-inflammatory 
therapy. 
 
TREATMENT 
 
AIMS OF ASTHMA TREATMENT 
 
 Minimal nocturnal and chronic symptoms 
 Minimal acute exacerbations 
 Near normal lung function test 
 PEF variability < 20% 
 No emergency room visit 
 Minimal use of beta agonist 
 No limitations of physical activities 
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Drugs used for bronchial asthma: 
 
 Bronchodilators 
 Controllers 
 
 
BRONCHODILATORS: 
 
 It acts on airway smooth muscles and relieves the 
bronchoconstriction. It gives a rapid relief of symptoms. It has little effect on 
inflammatory process. 
 
 Three classes of bronchodilators 
 Beta adrenergic agonists  
 Anticholinergics 
 Theophylline 
 
BETA 2 AGONISTS: 
 
 It acts on beta receptor, which joines with stimulatory G protein to 
adenyl cyclase, and it increases cyclic AMP to cause relaxation of smooth 
muscle cells of airways and inhibits the inflammatory cells like mast cells. 
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Effects of beta 2 agonists on airways: 
 
 Relax the airway smooth muscle 
 Inhibits the mediator from mast cells 
 Increased mucociliary clearance in airways 
 Inhibits the plasma exudation and airway oedema 
 Increase the mucus secretion 
 Decreased cough 
 No effect on inflammatory process 
 
 Beta 2 agonists are usually given by inhalation which can be 
divided in to 
 
 SABA (short acting beta 2 agonists) 
 LABA (long acting beta 2 agonists) 
 
 SABA – albuterol and terbutaline, has short life of 3-6 hrs. It is 
useful for symptom relief and exercise induced asthma. 
 
 LABA – salmeterol and formoterol, has duration of action for 
about 12 hrs. It is used in uncontrolled asthma. It should be used with Inhaled 
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corticosteroids and should not be given without ICS. It does not control 
underlying inflammation. 
 
 
Anticholinergics: 
 Ipratropium bromide, which prevents cholinergic nerve induced 
bronchoconstriction and mucus secretion. It is less effective than beta 2 
agonists. 
 
Theophylline: 
 It causes bronchodilatation by inhibiting the action of 
phophodiesterase enzyme in airway smooth muscle. In lower doses it has anti-
inflammatory effects. It activates the nuclear enzymes, histone deacetylase-2, 
which switch-off the activated inflammatory genes. 
 
CONTROLLER THERAPIES: 
Inhaled Corticosteroids: 
 ICS are the most effective anti-inflammatory agent in asthma 
therapy. It reduces the eosinophils in sputum and airways. It also reduces the 
mast cells and activated T cells in airways. This is the first line of treatment for 
bronchial asthma .If symptoms did not control with ICS, step up to LABA 
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Systemic Corticosteroids: 
 This can be used in oral and intravenous route. Intramuscular 
Triamcinolone acetonide is given like depot preparation in noncompliant 
persons 
 
OTHER CONTROLLER THERAPY: 
 Anti-leukotrienes - Montelukast, Zafirlukast 
 Cromones  - Cromolyn sodium, Nedocromil sodium 
 
MANAGEMENT OF CHRONIC ASTHMA: 
 All mild intermittent and persistent asthma treated with short acting 
beta-2 agonist. If symptoms were not controlled with short acting beta-2 
agonist, start inhalational corticosteroids and then add LABA. For treatment of 
chronic asthma stepwise approach was advised. 
              
 
 
STEPWISE APPROACH FOR CHRONIC ASTHMA 
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MATERIALS AND METHODS 
 
SETTING: 
          The study was conducted in Rajiv Gandhi government                              
general hospital, Chennai.  
  
DESIGN OF STUDY:  
                  It is an observational type of study. Interview technique was used to 
collect information on predesigned proforma. 
 
PERIOD OF STUDY: 
            This study was conducted in a time period from Jun 2013 to Nov 2013.  
 
SAMPLE SIZE: 
                             One hundred cases of bronchial asthma. 
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 INCLUSION CRITERIA: 
 
 All bronchial asthma patients 
 Age group between 20- 40 years of age 
 All the patients diagnosed clinically and satisfying the 
spirometric criteria were included in this study. 
 
 EXCLUSION CRITERIA: 
 
 COPD 
 Smoking 
 Age less than 20 years and more than 40 years 
 Pregnancy 
 Hypothyroidism  
 Co morbid conditions like Ischemic heart disease, congestive 
cardiac failure, valvular heart disease         
 Obstructive sleep apneoa     
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METHODS:    
 
 All asthma patients were selected from asthma clinic in the 
institute of internal medicine, Rajiv Gandhi Government general hospital, 
Chennai. Only 20 to 40 years old, known asthmatic patients were subjected to   
spirometry reversibility test and confirmed according to criteria. History was 
obtained from all the patients and the cases were subjected to pulmonary 
function tests. Patients were divided into four categories of bronchial asthma by 
severity based on GINA guidelines. 
 
Class1: Mild intermittent bronchial asthma 
Class2: Mild persistent bronchial asthma 
Class3: Moderate persistent bronchial asthma 
Class4: Severe persistent bronchial asthma 
 
 Body mass index was calculated according to Quetelet index by the 
formula,  
 BMI= weight (in kg) / height (in meter)2      
 
 
 According to the BMI, all patients were divided into three 
categories based on Indian standard. 
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• Class1: 18.5 to 22.9 - Normal 
• Class2: 23.0 to 24.9 - Overweight                    
• Class3:     >25   - Obese 
 
 All individuals were subjected to complete blood count 
examination, renal function test, liver function test, thyroid function test, chest 
X-ray, electrocardiogram, pulmonary function tests and C- reactive protein.     
C-reactive protein is an inflammatory mediator which is in obesity also. 
 
 All three categories of BMI were compared with four categories of 
severity class of bronchial asthma and analyzed for significant correlation. 
  
STATISTICAL ANALYSIS 
 All patients in the two categories were analyzed by Chi-square test 
and t-test for significance. 
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SPIROMETRY 
 Several tests are used to study various aspects of pulmonary 
functions. Among this, spirometry is the most basic and useful method. 
Spirometry is a simple test. It measures air flow from fully inflated lung 
overtime in litres. FVC, FEV1 and PEFR are calculated by spirometry.  
 
SELECTION OF SPIROMETER 
The American Thoracic society recommends that  
 It can be calibrated with a three litre syringe 
 It should record at least FVC and FEV1 
 It should record a flow-volume curve or a flow-volume loop or both(if 
possible) 
 
CONTRAINDICATIONS 
 Within 1 month of myocardial infarction 
 Recent abdominal surgery 
 
 Patients with any of the conditions listed below are unlikely to 
achieve optimal or reproducible results.  
• Chest or abdominal pain of any cause 
• Oral or facial pain exaggerated by a mouth piece 
• Stress incontinence 
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• Dementia or confused state 
 
PERFORMING SPIROMETRY 
 According to current ATS statement, a spirometry may be 
performed either in sitting or standing position. Sitting position is considered 
safe. In obese subject, standing positions may be preferred.  
 
THINGS TO AVOID BEFORE TEST 
 Smoking within one hour of test  
 Consuming alcohol within four hours of test 
 Performing vigorous exercise within thirty minutes of testing 
 Wearing clothes that substantially restrict chest wall and abdominal 
expansion 
 Eating large meal within two hours of  test 
 
SPIROMETRIC MANEUVER 
 The procedure was instructed and demonstrated to the patient. The 
patient then performs spirometry in following steps. 
 
Expiratory maneuver 
• Take a full deep breath away from the spirometer 
• Hold the mouth piece between the lips to get a good seal 
• Expire as fast and as hard as possible  until no breath is left 

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Expiratory and inspiratory maneuver 
i. Hold the mouth piece between the lips to get a good seal 
ii. Breath in and out for two to three tidal breaths 
iii. Expire as fast and as hard as possible until no breath is left 
iv. Inspire rapidly to maximum capacity 
 
REVERSIBILITY TESTING 
 Spirometry is recorded fifteen to thirty minutes after administration 
of short acting beta-2 agonists. Eg.200 to 400 microgram of salbutamol is used  
Calculation of percentage improvement 
   
FEV1 (post bronchodilator) – FEV1 (baseline) ×100 
    FEV1 (baseline)  
 Good bronchodilator reversibility is indicated by improvement in 
FEV1 by 200 ml and >12% of previous values 
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OBSERVATION AND RESULTS 
 
 
TABLE-1 
AGE DISTRIBUTION 
 
AGE(YEARS) 
 
NUMBER 
 
PERCENTAGE % 
 
20-25 
 
36 
 
36 
 
26-30 
 
15 
 
15 
 
31-35 
 
16 
 
16 
 
36-40 
 
33 
 
33 
 
Total  
 
100 
 
100 
 
                             In our study, 100 patients were included. All are adult age 
group between 20-40years. In this, the major age group is 20-25 years (n=36). 
The least age group is between 26-30 years (n=15)                                                                                   
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CHART-1 
AGE DISTRIBUTION  
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TABLE-2 
AGE – SEX DISTRIBUTION 
 
 
AGE GROUPS 
(IN YEARS) 
 
 
MALE 
 
FEMALE  
 
TOTAL  
 
20 – 25 
  
 
16 
 
20 
 
36 
 
26 – 30 
  
 
6 
 
9 
 
15 
 
31 – 35 
  
 
8 
 
8 
 
16 
 
36 – 40   
 
 
12 
 
21 
 
33 
 
Total  
 
 
42 
 
58 
 
100 
                                                                                                                                                                           
 
        In our study, out of 100 patients, 58 female were affected by asthma only 
42 male were involved. In female, the most common age group is between 36-
40years. In male, the common age group in our study is between 20-25 years. In 
this study, male are affected earlier than female  
AGE 
 
Sex ratio of this study group is 1:1.4
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TABLE-3 
BMI Distribution 
 
 
BMI CLASS 
 
NUMBER 
 
PERCENTAGE % 
 
I  -NORMAL 
 
61 
 
61 
 
II-OVERWEIGHT 
 
10 
 
10 
 
III- OBESITY 
 
29 
 
29 
 
Total 
 
100 
 
100 
 
                    Out of 100patients were studied, classified into three category of 
BMI based on Indian type. Large number of patients are under the category of 
normal BMI (n=61). Least number of patients are under the category of 
overweight BMI (n=10). 
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CHART 3 
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TABLE-4 
AGE & BMI DISTRIBUTION 
 
 
BMI 
CLASS 
 
  
  
AGE IN YEARS 
 
TOTAL 
  20-25 26-30 31-35 36-40 
I Count 32 7 11 11 61 
  % within 
Class of BMI 52.5% 11.5% 18.0% 18.0% 100.0% 
  % within Age 
in years 88.9% 46.7% 68.8% 33.3% 61.0% 
  
     
II Count 2 2 1 5 10 
  % within 
Class of BMI 20.0% 20.0% 10.0% 50.0% 100.0% 
  % within Age 
in years 5.6% 13.3% 6.3% 15.2% 10.0% 
  
     
III Count 2 6 4 17 29 
  % within 
Class of BMI 6.9% 20.7% 13.8% 58.6% 100.0% 
  % within Age 
in years 5.6% 40.0% 25.0% 51.5% 29.0% 
       
                                 
Total 
 
36 
 
15 
 
16 
 
33 
 
100 
 
     
 
     
 
                 In three group of BMI, highest is class I. Among the class I, highest 
age group is between 20-25 years (n=32). Among the study , least number of 
patients involved in  class II and age group between 31-35 years (n=1) 
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TABLE-5 
SEX & BMI DISTRIBUTION 
CLASS OF 
BMI 
 
 
  
  
 
SEX 
 
Total 
  
MALE 
 
FEMALE 
 
I Count 31 30 61 
% within Class of 
BMI 50.8% 49.2% 100.0% 
% within Sex 73.8% 51.7% 61.0% 
 
 
II 
 
Count 
 
4 
 
6 
 
10 
% within Class of 
BMI 40.0% 60.0% 100.0% 
% within Sex 9.5% 10.3% 10.0% 
 
III 
 
Count 
 
7 
 
22 
 
29 
% within Class of 
BMI 24.1% 75.9% 100.0% 
% within Sex 16.7% 37.9% 29.0% 
  
 
Total  
 
 
42 
 
 
58 
 
 
100 
    
 
            In our study, Female is the overall highest group (n=58). In class I sex 
ratio is 1:1. Sex ratio in class II is 1:1.5. Sex ratio in class III is 1:2. Male group 
is highest in class I (n=31) 
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TABLE-6 
DISTRIBUTION OF SEVERITY OF BRONCHIAL ASTHMA 
 
CLASS 
 
NUMBER 
 
PERCENTAGE% 
I- Mild intermittent 17 17 
II- Mild persistent 39 39 
III- Moderate persistent 24 24 
IV- Severe persistent 20 20 
Total 100 100 
 
                    Out of 100 patients, who were divided into four class of severity of 
asthma, more number of patients came under class II (n=39). Least number of 
patients came under class I (n=17) 
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CHART-4 
SEVERITY OF BRONCHIAL ASTHMA
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TABLE-7 
CORRELATION BETWEEN AGE & SEVERITY OF ASTHMA 
 
Age in 
years 
 
 
  
  
Severity Class of Asthma 
Total 
 
  
 
 
P value 
I II III IV 
20-25 Count 8 15 10 3 36  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.612 
 
 
Not 
significant 
  % within 
Age in 
years 
22.2% 41.7% 27.8% 8.3% 100.0% 
  % within 
Severity 
Class of 
Asthma 
47.1% 38.5% 41.7% 15.0% 36.0% 
26-30 Count 2 7 2 4 15 
  % within 
Age in 
years 
13.3% 46.7% 13.3% 26.7% 100.0% 
  % within 
Severity 
Class of 
Asthma 
11.8% 17.9% 8.3% 20.0% 15.0% 
31-35 Count 3 6 4 3 16 
  % within 
Age in 
years 
18.8% 37.5% 25.0% 18.8% 100.0% 
  % within 
Severity 
Class of 
Asthma 
17.6% 15.4% 16.7% 15.0% 16.0% 
36-40 Count 4 11 8 10 33 
  % within 
Age in 
years 
12.1% 33.3% 24.2% 30.3% 100.0% 
  % within 
Severity 
Class of 
Asthma 
23.5% 28.2% 33.3% 50.0% 33.0% 
 
Total  17 39 24 20 
 
100 
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CHART-5 
CORRELATION BETWEEN AGE & SEVERITY OF ASTHMA 
 
 
 In this study, the higher number of patients are in the age group 
between 20-25 years (n=15). Chi square test was applied to test the significance 
between age group and severity of bronchial asthma. There was no significant 
difference (p=0.65) was found between the two variables. 
 
 
Age in years
36-4031-3526-3020-25
Count
16
14
12
10
8
6
4
2
0
Severity Class of Asthma
I
II
III
IV
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TABLE-8 
CORRELATION BETWEEN SEX & SEVERITY OF ASTHMA 
 
SEX 
  
  SEVERITY CLASS OF ASTHMA 
TOTAL 
  
 
 
P VALUE 
  I II III IV 
Male Count 14 20 3 5 42  
 
 
 
 
 
<0.001 
 
SIGNIFICANT 
  
  
% within 
Sex 33.3% 47.6% 7.1% 11.9% 100.0% 
% within 
Severity 
Class of 
Asthma 
82.4% 51.3% 12.5% 25.0% 42.0% 
Female Count 3 19 21 15 58 
  
  
% within 
Sex 5.2% 32.8%% 36.2% 25.9% 100.0% 
% within 
Severity 
Class of 
Asthma 
17.6% 48.7% 87.5%% 75.0% 58.0% 
 TOTAL 17 39 24 20 100 
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CHART-6 
         CORRELATION BETWEEN SEX & SEVERITY OF ASTHMA 
 
 
 Out of 100 patients studied, majority of male patients came under 
the asthma severity class II & I and majority of female patients came under 
asthma severity class III & II. Among the asthma severity class III & IV, 
majority of them was females. It showed significant (p=<0.001) correlation 
between sex and severity of asthma 
 
Sex
FemaleMale
Count
30
20
10
0
Severity Class of Asthma
I
II
III
IV


TABLE-9 
CORRELATION BETWEEN OCCUPATION &  
SEVERITY OF ASTHMA 
Occupation 
 
  
  
Severity Class of Asthma 
 
Total 
  
 
I II III IV 
P value 
 
 House wife  Count 3 24 10 12 49  
   % within 
Occupation 6.1% 49.0% 20.4% 24.5% 100.0% 
 
    
% within 
Severity 
Class of 
Asthma 
17.6% 61.5% 41.7% 60.0% 49.0% 
 
 
Agricultural 
work 
 
 
 
Count 10 10 8 4 32 
 
    
% within 
Occupation 
31.3% 31.3% 25.0% 12.5% 100.0% 
 
    
% within 
Severity 
Class of 
Asthma 
58.8% 25.6% 33.3% 20.0% 32.0% 
 
 
Office work 
 
 
 
Count 0 1 3 2 6 
0.058 
 
 
SIGNIFICANT 
   % within 
Occupation .0% 16.7% 50.0% 33.3% 100.0% 
 
    
% within 
Severity 
Class of 
Asthma 
.0% 2.6% 12.5% 10.0% 6.0% 
 
 
Others 
 
 
 
Count 4 4 3 2 13 
 
    
% within 
Occupation 
30.8% 30.8% 23.1% 15.4% 100.0% 
 
    
% within 
Severity 
Class of 
Asthma 
23.5% 10.3% 12.5% 10.0% 13.0% 
 
 
 
 
Total  17 39 24 20 100 
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CHART-7 
CORELATION BETWEEN OCCUPATION & SEVERITY OF ASTHMA 
 
 
 In our study, majority of patients were house wife (n=49) followed 
by agricultural workers. Chi square test showed significant (p=0.058) 
correlation. 
 
 
 
Occupation
OthersOffice workAgricultural 
work 
House wife
Count
30
20
10
0
Severity Class of Asthma
I
II
III
IV
	

TABLE-10 
CORRELATION BETWEEN BMI & SEVERITY OF ASTHMA 
 
CLASS 
OF BMI 
 
  
  
SEVERITY CLASS OF ASTHMA 
 TOTAL 
  
 
P VALUE 
I II III IV 
I Count 13 32 14 2 61  
 
 
 
 
 
 
 
 
 
<0.001 
 
SIGNIFICANT 
  % within 
Class of 
BMI 
21.3% 52.5% 23.0% 3.3% 100.0% 
  % within 
Severity 
Class of 
Asthma 
76.5% 82.1% 58.3% 10.0% 61.0% 
II Count 2 4 3 1 10 
  % within 
Class of 
BMI 
20.0% 40.0% 30.0% 10.0% 100.0% 
  % within 
Severity 
Class of 
Asthma 
11.8% 10.3% 12.5% 5.0% 10.0% 
III Count 2 3 7 17 29 
  % within 
Class of 
BMI 
6.9% 10.3% 24.1% 58.6% 100.0% 
  % within 
Severity 
Class of 
Asthma 
11.8% 7.7% 29.2% 85.0% 29.0% 
  
Total  
 
17 39 24 20 100 
 
 
 
 
 
 
 
 

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CHART-8 
CORRELATION BETWEEN BMI & SEVERITY OF ASTHMA 
 
 
 In our study, the majority of patients with BMI class III came 
under class IV of asthma severity. Chi square applied showed significance 
(p=<0.001). It implies that obese patients are at increased risk of developing 
bronchial asthma. 
 
 
Class of BMI
IIIIII
Count
40
30
20
10
0
Severity Class of Asthma
I
II
III
IV
	

TABLE-11 
CORRELATION BETWEEN SPO2 AND SEVERITY OF ASTHMA 
 
SPO2  % 
 
 
  
 
SEVERITY CLASS OF ASTHMA 
 
 
TOTAL 
 
  I II III IV   
93-95 Count 0 5 22 20 47 
  % within 
Spo2  % .0% 10.6% 46.8% 42.6% 100.0% 
  % within 
Severity 
Class of 
Asthma 
.0% 12.8% 91.7% 100.0% 47.0% 
 
96-97 
 
Count 
 
8 
 
26 
 
2 
 
0 
 
36 
  % within 
Spo2  % 22.2% 72.2% 5.6% .0% 100.0% 
  % within 
Severity 
Class of 
Asthma 
47.1% 66.7% 8.3% .0% 36.0% 
 
98-99 
 
Count 
 
9 
 
8 
 
0 
 
0 
 
17 
  % within 
Spo2  % 52.9% 47.1% .0% .0% 100.0% 
  % within 
Severity 
Class of 
Asthma 
52.9% 20.5% .0% .0% 17.0% 
  
 
Total  
 
 
17 
 
 
39 
 
 
24 
 
 
20 
 
 
100 
      
      
 
 
 
 
	

CHART 9 
CORRELATION BETWEEN SPO2 AND SEVERITY OF ASTHMA 
 
 
 In this study, the SPo2 varies from 93% – 99% according to the 
asthma severity. The majority of patients in class IV asthma severity had SpO2 
between 93% to 95% and class I asthma severity had SpO2 between 98% to 
99%. 
 
 
SpO2 %
98-9996-9793-95
Count
30
20
10
0
Severity Class of Asthma
I
II
III
IV
	

TABLE-12 
CORRELATION BETWEEN FEV1/FVC RATIO & SEVERITY OF 
ASTHMA 
 
FEV1/FVC 
 
  
 
SEVERITY CLASS OF ASTHMA 
 
TOTAL 
 
  I II III IV   
< 0.5 Count 0 0 1 12 13 
  % within 
FEV1/FVC .0% .0% 7.7% 92.3% 100.0% 
  % within 
Severity 
Class of 
Asthma 
.0% .0% 4.2% 60.0% 13.0% 
 
 
0.5-0.7 
 
 
Count 
 
 
1 
 
 
10 
 
 
23 
 
 
8 
 
 
42 
  % within 
FEV1/FVC 2.4% 23.8% 54.8% 19.0% 100.0% 
  % within 
Severity 
Class of 
Asthma 
5.9% 25.6% 95.8% 40.0% 42.0% 
 
 
> 0.7 
 
 
Count 
 
 
16 
 
 
29 
 
 
0 
 
 
0 
 
 
45 
  % within 
FEV1/FVC 35.6% 64.4% .0% .0% 100.0% 
  % within 
Severity 
Class of 
Asthma 
94.1% 74.4% .0% .0% 45.0% 
       
  
Total 
 
 
17 
 
39 
 
24 
 
 
20 
 
 
100 
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CHART-10 
CORRELATION BETWEEN FEV1/FVC RATIO & SEVERITY OF 
ASTHMA 
 
 
 
 In our study out of 100 patients, FEV1 / FVC ratio varies according 
to the asthma severity. Large number of patients in class IV had FEV1/FVC 
ratio < 0.5. 
FEV1/FVC
> 0.70.5-0.7< 0.5
Count
40
30
20
10
0
Severity Class of Asthma
I
II
III
IV
	

 
 
TABLE 13 
CORRELATION BETWEEN C-REACTIVE PROTEIN & BMI 
 
CLASS OF 
BMI 
 
  
 
C – REACTIVE PROTEIN 
(mg/L) 
 TOTAL 
  Increased Normal   
 
I 
 
Count 
 
3 
 
58 
 
61 
% within Class of 
BMI 4.9% 95.1% 100.0% 
% within C – 
Reactive Protein 
(mg/L) 
8.3% 90.6% 61.0% 
 
 
II 
 
 
Count 
 
 
7 
 
 
3 
 
 
10 
% within Class of 
BMI 70.0% 30.0% 100.0% 
% within C – 
Reactive Protein 
(mg/L) 
19.4% 4.7% 10.0% 
 
 
III 
 
 
Count 
 
 
26 
 
 
3 
 
 
29 
% within Class of 
BMI 89.7% 10.3% 100.0% 
% within C – 
Reactive Protein 
(mg/L) 
72.2% 4.7% 29.0% 
  
 
 
 
 
 
 
 
  
Total 
 
36 
 
64 
 
100 
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CHART-11 
CORRELATION BETWEEN C-REACTIVE PROTEIN & BMI 
 
 
 In this study, out of 100 patients 36 patients had elevated C-
reactive protein. Among this majority came under BMI Class III (72%). Chi 
square test showed significant (p=<0.001) correlation between the two 
variables. It implies that with increasing BMI, there is increase in C-reactive 
protein also. 
 
Class of BMI
IIIIII
Count
70
60
50
40
30
20
10
0
C – Reactive Protein
Increased
Normal
	

TABLE-14 
MORBIDITY AND SEVERITY OF BRONCHIAL ASTHMA 
 
 
S.No  
 
MORBIDITY 
 
SEVERITY OF ASTHMA 
 
BMI 
 
I 
 
II 
 
III 
 
IV 
 
I 
 
II 
 
III 
 
1 
 
Previous life 
threatening 
event 
 
0 
 
0 
 
2 
 
4 
 
1 
 
1 
 
4 
 
2 
 
Missed working 
days 
 
0 
 
1 
 
6 
 
11 
 
3 
 
3 
 
12 
 
 
 In our study, patients with previous life threatening event and 
missed working days came under asthma severity class IV and BMI class III. 
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RESULTS AND SUMMARY 
 
 In this study 100 known asthmatic patients studied who were confirmed 
with reversibility spirometry test. 
 
 Out of 100 patients 42 were male and 58 were female. Sex ratio was 1:1.4 
 
  In this study, 20-40 years age group adult patients were included for 
study. In this most of them were between 20-25 years of age. 
 
 Out of 100 patients, 61 patients were under BMI class I, 10 patients under 
BMI class II, and 29 patients under BMI class III. Majority of obese 
(BMI class III) were female. 
 
 Out of 100 patients, 17 were under asthma severity class I, 39 under 
severity class II, 24 were under severity class III and 20 were under 
severity class IV. 
 
 
 
 
		

 In this study, no significant relationship was found between age and 
severity of asthma. 
 
 In our study, sex had significant correlation with severity of asthma. 
Majority of female patients came under the asthma severity class IV. 
 
 Majority of house wife and agricultural workers had asthma. Significant 
relationship was found between occupation and severity of asthma. 
 
 In this study, majority of patients with asthma severity class III & IV had 
low oxygen saturation than class I & II. 
 
 Out of 100 patients, the majority of patients with asthma severity class IV 
& III had low FEV1/FVC ratio. 
 
 In our study, majority of patients with BMI class III had increased C-
reactive protein. There is significant relationship present between BMI 
and C-reactive protein. It implies that obesity is a pro-inflammatory 
condition. 
 
 
	


 In our study, patients with BMI class III and asthma severity class IV had 
increased morbidity by decreasing working days and increasing life 
threatening events  when compared with other classes. 
 
 In our study, out of 100 patients majority of patients with BMI class III 
had severe persistent (class IV) asthma. It showed the significant 
correlation between obesity and bronchial asthma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


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DISCUSSION 
 
 Approximately 65% of adults in worldwide aged 20 or above are 
either overweight or obese. This indicates 10% increase of obesity prevalence 
from previous decades of life. The national health & nutrition examination 
survey III estimated the adult obesity prevalence to be 18% to 23% by recent 
data. The behavioral risk factor surveillance system estimated the prevalence of 
obesity to be 20%.  
 
 Similar to the obesity epidemics, there is also increased prevalence 
of asthma. Obesity and asthma are major health problem worldwide. Due to the 
concurrent increase in asthma and obesity prevalence, many studies have 
reported that there is association between obesity and higher asthma prevalence. 
This association shows that obesity is a risk factor for asthma which was 
strengthened by many meta-analysis studies.  
 
 Obesity is also associated with bronchial hyper responsiveness. 
Finally a number of studies showed weight loss can improve both the 
physiological and clinical improvement of asthma.  
 
 



 Akerman et al, explained that there is increased risk of asthma in 
adults with obesity. 143 individuals were involved in this study which showed 
significant relation. 
 
 Saint – Pierre et al, explained that the patients with severe 
persistent asthma were more likely to be overweight compared to those with 
mild and moderate persistent asthma. 
 
 Lavoie et al, demonstrated that obese adults with asthma had poor 
asthma control, quality of life and use the long acting beta 2 agonists. 
 
 Camargo et al, found that the BMI, as measured in 1991, strongly 
correlated with the risk of development of adult onset of asthma in the 
following 4 years.  
 
 In our study, 100 known asthmatic patients between 20-40 years 
age group, confirmed with reversibility spirometry test were studied. Among 
this 42 were male and 58 were female. In this majority of patients were in BMI 
class I and majority of female patients were under BMI class III. Obese patients 
(BMI class III) significantly related with severe persistent and moderate 
persistent asthma (asthma severity class IV & III). The majority of patients in 
class IV severity of asthma had low FEV1/FVC ratio and low SpO2 levels than 



other groups. Class IV asthma severity patients and BMI class III patients had 
more morbidity by decreasing working days and precipitating life threatening 
events than others. 
 
 Chen et al, showed that obesity is more strongly associated with 
non allergic asthma than allergic asthma. The non allergic asthma is more 
prevalent in women than men.  
 
 In our study, the female group was significantly related with class 
IV asthma severity. Majority of female patients were under BMI class III. 
 
 Delgado et al, revealed that obesity is a pro-inflammatory 
condition in which C-reactive protein and other inflammatory mediators are 
raised.  
 
 In our study, there is significant raise of C-reactive protein with 
majority of obese individuals. 
 
 
 
 
 


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LIMITATIONS OF STUDY 
  
 Small study group is involved. 
 
 Duration of study is short. 
 
 In asthma patients, weight may be increased with treatment like steroids, 
which could not be excluded in this study. 
 
 Asthma is a multi factorial disease. All the factors could not be measured 
in this study. 
 
 
 
 
 
 
 
 
 
 



 
CONCLUSION  
 
 Obesity is a major burden in asthmatics. It increases the morbidity 
in asthmatic patients by decreasing working days and precipitating life 
threatening events. Obesity decreases oxygen saturation, FVC and FEV1/FVC 
ratio in asthmatic patients. 
 
 Obese female are particularly at increased risk of worsening 
symptoms of asthma. Obesity is a pro-inflammatory condition, which releases 
inflammatory mediators like C-reactive protein. Finally, obesity and overweight 
are significantly related with severity of asthma which increases the frequency 
of symptoms and life threatening events. 
 
 As obesity and asthma have considerable impact on public health, 
the first and foremost, weight control programme must be included in treatment 
plan of the obese asthmatic patients with other measures. 
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ANNEXURE 
 








 

PROFORMA 
 
Name   :     Body weight : 
Age / sex  :      Height  : 
IP / OP No  :     BMI   : 
Occupation   : 
Address  : 
Contact No  : 
 
COMPLAINTS: 
Cold   Sneezing  Cough  Snoring during sleep  
Wheeze  ________episode/month _________episode/year 
Wheeze without breathlessness _      _____episode/month _________episode/year 
Night time wheeze   > 1 per week < 1 per week absent 
Symptoms of waking  > 1 per week < 1 per week absent 
Admission or emergency unit_________ / month __________ / year 
Previous life threatening attack  Present / Absent _______ times 
Missed work days 
 
PAST HISTORY: 
DM   CAD   SHT   TB 
Epilepsy  Hypothyroidism   COPD 
Bronchial asthma  ______ years 
 TREATMENT HISTORY: 
Short acting beta 2 agonist – any use 
Short acting beta 2 agonist – daily use 
Long acting beta 2 agonis 
Anticholinergics  
Methylxanthine 
Leukotriene antagonists 
Cromolyn  
Inhaled corticosteroids 
Oral corticosteroids 
 
PERSONAL HISTORY: 
Smoker 
Alcoholic  
 
FAMILY HISTORY: 
Consanguinous marriage 
Similar history to ____________ 
 
 
 
 
GENERAL EXAMINATION: 
 
 
 
VITALS: 
 
Systemic examination: 
Respiratory system: 
 Upper respiratory tract 
 Lower respiratory tract 
Cardio-vascular system: 
Per abdomen: 
Central nervous system: 
 
Investigations: 
CBC:      Thyroid Function Test: 
 
RFT:      C-reactive protein: 
 
LFT:      Chest X-ray: 
 
 ECG:   SpO2:  Pulmonary function test: 
 
 
 
 PATIENT CONSENT FORM 
 
Study Title : ‘’ASSESSMENT OF CLINICAL CORRELATION 
BETWEEN BODY MASS INDEX AND 
SEVERITY OF BRONCHIAL ASTHMA” 
 
 
Study Centre : Institute of Internal Medicine & Department of 
Thoracic Medicine, Rajiv Gandhi Government General 
Hospital, Chennai. 
 
 
Patient’s Name :  
 
Patient’s Age :  
 
Identification 
Number 
: 
 
 
 
 
Patient may check () these boxes 
 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. 
 
 o 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
 
 o 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities o 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
 
 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and 
to immediately inform the study staff if I suffer from any deterioration 
in my health or well being or any unexpected or unusual symptoms. 
 
 o 
I hereby consent to participate in this study. 
 
 o 
I hereby give permission to undergo complete clinical examination , 
biochemical, immunological test. o 
 
 
Signature/thumb impression 
 
 
Patient’s Name and Address: 
 
 
Signature of Investigator 
 
 
Study Investigator’s Name:     Dr. P. RAJA 
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 M – Male HW – Housewife  
F – Female  AW – agricultural worker 
  OW – office worker  
  CW – company worker 
  AD – Auto driver 
  S – Student  
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